We are live on ! Find out more
VERA icon

Vera Therapeutics

177 hedge funds and large institutions have $1.89B invested in Vera Therapeutics in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 67 increasing their positions, 48 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

40% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 48

12% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 33

10% more capital inflows, than outflows

Capital inflows: $279M | Capital outflows: $253M

2% more funds holding

Funds holding: 173 → 177 (+4)

1.75% more ownership

Funds ownership: 100.2% → 101.95% (+1.8%)

48% less call options, than puts

Call options by funds: $2.68M | Put options by funds: $5.15M

Holders
177
Holders Change
+4
Holders Change %
+2.31%
% of All Funds
2.31%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.09%
New
37
Increased
67
Reduced
48
Closed
33
Calls
$2.68​M
Puts
$5.15​M
Net Calls
-⁠$2.47​M
Net Calls Change
-⁠$29.7​M

VERA Hedge Fund Activity: Q3 2025 in Review

177 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2025, worth a combined $1.89B — up 26% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new VERA positions and 33 closed out — a net gain of 4 holders — while 67 added to existing stakes and 48 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $29.4M. The largest seller was Vestal Point Capital, cutting an estimated $54.1M.

  • 177 institutional investors held Vera Therapeutics (VERA) as of Q3 2025, up from 173 in Q2 2025.
  • Funds reported $1.89B of Vera Therapeutics stock for Q3 2025, up 26% quarter-over-quarter.
  • 37 funds opened new Vera Therapeutics positions in Q3 2025 and 33 closed out, a net change of +4 holders.
  • The largest Vera Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $29.4M added.
  • The largest Vera Therapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $54.1M sold.

Based on aggregated 13F filings for Q3 2025.